Chemomab Therapeutics (CMMB) Current Assets (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Current Assets data on file, last reported at $13.4 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 16.3% year-over-year to $13.4 million; the trailing twelve-month figure through Dec 2025 stood at $13.4 million (down 16.3% YoY), and the FY2025 full-year result was $13.4 million, down 16.3% from the prior year.
• Current Assets for Q4 2025 stood at $13.4 million, up from $11.9 million in the prior quarter.
• Across five years, Current Assets topped out at $68.8 million in Q2 2021 and bottomed at $10.6 million in Q2 2025.
• The 5-year median for Current Assets is $25.0 million (2023), against an average of $34.0 million.
• The widest annual swing landed in 2021, when Current Assets jumped 791.2%; it then tumbled 54.1% in 2023.
• A 5-year view of Current Assets shows it stood at $62.7 million in 2021, then tumbled by 33.42% to $41.7 million in 2022, then tumbled by 49.93% to $20.9 million in 2023, then declined by 23.24% to $16.0 million in 2024, then decreased by 16.3% to $13.4 million in 2025.
• The last three Current Assets figures came in at $13.4 million (Q4 2025), $11.9 million (Q3 2025), and $10.6 million (Q2 2025), per Business Quant data.

Peer Comparison